こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

March 2, 2018

Company:	DyDo Group Holdings, Inc.
Representative:	Tomiya Takamatsu, President and Representative Director
	(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries:	Naokazu Hasegawa, Corporate Officer
	and General Manager of Corporate Communication Department

DyDo Group to Enter the Orphan Drug Business

The DyDo Group is pleased to announce its entry into the orphan drug* business in July 2019.

1. Reason for entering this new business

The Group, which has identified the “Challenge to establish new business foundations” as one of its medium- and long-term growth strategies, has hired specialized personnel to staff a Strategic Investment Group in the Corporate Strategy Department as part of an effort to study the potential of new businesses in the rapidly growing field of life science and other segments of the healthcare domain.

To be classified as a orphan drug, a pharmaceutical must be intended for use against a difficult-to-treat disease with fewer than 50,000 patients; highly medically necessary; unique in that there are no alternative, appropriate treatments or drugs; and highly effective or safe compared to existing pharmaceuticals, among other criteria. Although the number of pharmaceutical companies developing orphan drugs is growing, the small patient population means that development remains inadequate. There are numerous diseases for which there is no effective treatment drug, making the area one of urgent social need.

We will enter the orphan drug business in July 2019 in an effort to help resolve social issues through our business operations in accordance with our philosophy of “striving to achieve happiness and prosperity with people and society as a whole” by “continuing our dynamic efforts to take on new challenges.”

We will strive to help all group stakeholders realize happiness by providing value through pharmaceuticals for patients suffering from rare diseases.

2. Future plans

The Group has provided value and delicious flavor to customers in the form of a selection of drink and food products that includes canned coffee and other soft drinks, nutrition and beauty drinks, and fruit dessert jellies.

To develop new markets in response to future changes in population demographics and lengthening healthy life expectancy and deliver products that will inspire consumer loyalty over the long term, we believe that it will be essential to go beyond products that simply taste great by enhancing our drinks and foods so that they offer even better flavor while contributing to health in everyday life. As we strive to cultivate healthcare-related markets that go beyond conventional drink, food, and pharmaceutical categories and tap them as a major source of future revenue, we believe that obtaining knowledge related to health and pharmaceuticals by adding the field of life sciences to our business domain will serve to lay the groundwork for increasing our corporate value over the medium and long term.

Going forward, we will continue to embrace the challenge of providing customers with delicious and healthy products and services—in short, products and services that live up to our Group slogan of “offering delicious products for the sound mind and body.”

Because we plan to launch our new orphan drug business in July 2019, associated operations will have only a slight impact on consolidated business results during the fiscal year ending 20, January 2019.

*As defined by Article 77 Paragraph 2 of Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.